NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of loxapine inhalation for treating mild to moderate agitation in adults with schizophrenia or bipolar disorder. If, after doing this, organisations still wish to consider loxapine inhalation for treating mild to moderate agitation in adults with schizophrenia or bipolar disorder, they should follow the advice set out in the Department of Health's Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance, which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.
NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.
For information about NICE guidance that has been issued or is in development, see the NICE website.
Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). NICE clinical guideline 82 (2009).
The management of bipolar disorder in adults, children and adolescents in primary and secondary care. NICE clinical guideline 38 (2006).
Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. NICE clinical guideline 25 (2005).